-
Tytuł:
-
Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19.
-
Autorzy:
-
Li M; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Dong Y; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wang H; Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Guo W; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhou H; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhang Z; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Tian C; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Du K; Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhu R; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Wang L; Department of Emergency Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhao L; Department of Infectious Disease, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Fan H; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Luo S; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hu D; Department of Integrated Traditional Chinese and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. Electronic address: .
-
Źródło:
-
Nutrition, metabolism, and cardiovascular diseases : NMCD [Nutr Metab Cardiovasc Dis] 2020 Jun 25; Vol. 30 (7), pp. 1061-1067. Date of Electronic Publication: 2020 Apr 18.
-
Typ publikacji:
-
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2005- : Amsterdam : Elsevier
Original Publication: [Heidelberg] : Springer International, c1991-
-
MeSH Terms:
-
Betacoronavirus*
Cause of Death*
Disease Progression*
Cardiovascular Diseases/*epidemiology
Coronavirus Infections/*epidemiology
Disease Outbreaks/*statistics & numerical data
Pneumonia, Viral/*epidemiology
Adult ; Aged ; Biomarkers/blood ; Blood Chemical Analysis ; C-Reactive Protein/metabolism ; COVID-19 ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/therapy ; China/epidemiology ; Cohort Studies ; Comorbidity ; Coronavirus Infections/diagnosis ; Coronavirus Infections/therapy ; Databases, Factual ; Female ; Humans ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/diagnosis ; Pneumonia, Viral/therapy ; Reference Values ; Retrospective Studies ; SARS-CoV-2 ; Survival Analysis ; Tomography, X-Ray Computed/methods
-
References:
-
N Engl J Med. 2015 Apr 2;372(14):1333-41. (PMID: 25830423)
JAMA. 2003 Jun 4;289(21):2801-9. (PMID: 12734147)
N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
JAMA. 2020 Mar 17;323(11):1061-1069. (PMID: 32031570)
N Engl J Med. 2020 Apr 30;382(18):1708-1720. (PMID: 32109013)
Cytokine. 2018 Apr;104:8-13. (PMID: 29414327)
Am J Public Health. 2019 Sep;109(9):1288-1293. (PMID: 31318592)
Lancet Infect Dis. 2013 Sep;13(9):752-61. (PMID: 23891402)
Circ Res. 2016 Apr 15;118(8):1313-26. (PMID: 27081112)
Circ Res. 2000 Sep 1;87(5):E1-9. (PMID: 10969042)
Lancet Oncol. 2020 Mar;21(3):335-337. (PMID: 32066541)
Sci Rep. 2017 Sep 12;7(1):11307. (PMID: 28900101)
J Biol Chem. 2000 Oct 27;275(43):33238-43. (PMID: 10924499)
Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Lancet Respir Med. 2020 May;8(5):475-481. (PMID: 32105632)
N Engl J Med. 2020 Mar 26;382(13):1199-1207. (PMID: 31995857)
Postgrad Med J. 2006 Feb;82(964):140-4. (PMID: 16461478)
Circ Res. 2019 Mar;124(5):747-756. (PMID: 30727837)
Int J Infect Dis. 2016 Aug;49:129-33. (PMID: 27352628)
Radiology. 2004 Mar;230(3):836-44. (PMID: 14990845)
Circulation. 2005 May 24;111(20):2605-10. (PMID: 15897343)
Clin Exp Immunol. 2004 Apr;136(1):95-103. (PMID: 15030519)
Circulation. 2017 Mar 7;135(10):e146-e603. (PMID: 28122885)
-
Contributed Indexing:
-
Keywords: COVID-19; Cardiovascular disease; Prognosis
-
Substance Nomenclature:
-
0 (Biomarkers)
9007-41-4 (C-Reactive Protein)
-
Entry Date(s):
-
Date Created: 20200528 Date Completed: 20200630 Latest Revision: 20240328
-
Update Code:
-
20240329
-
PubMed Central ID:
-
PMC7165120
-
DOI:
-
10.1016/j.numecd.2020.04.013
-
PMID:
-
32456948
-
Background and Aim: A novel coronavirus severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) caused pneumonia, Coronavirus Disease 2019 (COVID-19), broke out in Wuhan, China in December 2019, and spread all over the world. Patients with COVID-19 showed huge differences in the hospital stay, progression, and prognosis. As reported, the comorbidities may play an important role in COVID-19. Here, we aim to address the role of cardiovascular disease (CVD) in the progression and prognosis of COVID-19.
Methods and Results: Eighty-three confirmed COVID-19 patients were divided into CVD (n = 42) and non-CVD (n = 41) group according to their medical history. Medical records including demographic data, medical history, clinical characteristics, laboratory examinations, chest computed tomography (CT), and treatment measures were collected, analyzed, and compared between the two groups. COVID-19 patients with CVD showed (1) more severe pathological changes in the lungs, (2) elevated injury-related enzymes including α-hydroxybutyrate dehydrogenase (HDBH), lactic dehydrogenase (LDH), γ-glutamyltransferase (GGT), creatine kinase (CK), and alanine aminotransferase (ALT), (3) significantly increased uncontrolled inflammation related markers, such as c-reactive protein (CRP), interleukin (IL)-6, serum ferritin, erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA), (4) serious hypercoagulable status reflected by increased D-dimer and serum fibrinogen (FIB), and (5) higher mortality, compared to COVID-19 patients without CVD.
Conclusions: Our data indicated that CVD is a strong risk factor for rapid progression and bad prognosis of COVID-19. More intensive medical care should be applied to patients with CVD to prevent rapid deterioration of the disease.
Competing Interests: Declaration of Competing Interest The authors have no conflicts of interest to note.
(Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.)
